Thalidomide-O-amido-PEG1-(C1-​PEG)2-C2-NH2

Background Introduction

Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 is an E3 Ligase Ligand-Linker Conjugate designed for advanced applications in targeted protein degradation. With thalidomide as the active ligand moiety, this innovative compound exploits the well-characterized cereblon (CRBN) E3 ligase for the recruitment necessary in PROTAC (Proteolysis Targeting Chimera) technology. The inclusion of a flexible PEG-based linker provides optimal spatial orientation and enhances water solubility, making it suitable for efficient and selective target engagement in PROTAC development.

Mechanism

This molecule features a thalidomide-derived E3 ligase ligand tethered via a PEGylated linker to a reactive amine. The thalidomide segment specifically binds to the CRBN E3 ubiquitin ligase, serving as an anchor in the ternary complex formation essential for PROTAC-induced degradation. The PEG linker imparts flexibility, hydrophilicity, and reduces steric hindrance, thereby facilitating efficient proximity-induced ubiquitination when conjugated to a target protein ligand via its terminal amine. Such design enhances the overall bioavailability, target accessibility, and pharmacokinetic properties of custom PROTACs.

Applications

Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 is a versatile tool in the design and synthesis of PROTACs for chemical biology research and drug discovery. Its key applications include: (1) Synthesis of CRBN-based PROTAC molecules for targeted protein degradation studies; (2) Investigation of protein function via selective degradation in cellular and in vivo models; (3) Development of next-generation therapeutics for cancer, neurodegenerative, and immunological diseases; and (4) Exploration of linker length effects in SAR (structure-activity relationship) studies of bifunctional degrader compounds. This conjugate offers researchers a reliable starting point for modular assembly and optimization of custom degraders.

The Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 E3 Ligase Ligand-Linker Conjugate plays a crucial role in the development of PROTACs by facilitating targeted protein degradation. This conjugate combines a thalidomide-based ligand with a versatile linker, enabling precise protein targeting and degradation, thus enhancing the efficacy of therapeutic interventions. The following provides a detailed description of this molecule.

Linker: The linker in this molecule is composed of a PEG1-(C1-PEG)2-C2 chain, which offers moderate flexibility and appropriate length for bridging the ligand and target protein. Its cleavability ensures controlled release, optimizing the degradation process and enhancing selectivity.

Ligand: The ligand component is derived from thalidomide, known for its high affinity and specificity towards cereblon, an E3 ubiquitin ligase. This structural characteristic ensures effective recruitment of the target protein for ubiquitination and subsequent degradation.

Reactive Site: The reactive site is an amide group that couples with the target protein ligand. It is recommended to use amide bond formation reactions, such as peptide coupling reactions, to achieve efficient conjugation with the target protein warhead.

Recommended Target Protein Ligand: The compatible warhead for this molecule is typically a small-molecule inhibitor or peptide capable of binding the target protein with high affinity. This combination allows for enhanced specificity and potency in degrading disease-related proteins, thus offering a powerful tool for research in targeted protein degradation.